Inclusion Criteria:

Patients have baseline evaluations ≤14days prior to 1st dose of study drug unless
otherwise specified

- Patients with confirmed malignant glioma (MG) who are recurrence/relapse

- Patients may not have stereotactic tumor biopsy < 1 week or surgical resection or
open biopsy < 4 weeks before starting study drug

- For stratum of non-EIAED patients, each patient must be off all EIAEDs for > 2 weeks
prior to starting study drug; similarly for stratum of EIAED patients, each patient
must be on EIAED for >2 weeks prior to starting study drug

- Patients should be on non-increasing dose of steroids for >7 days prior to obtaining
baseline MRI with gadolinium (Gd-MRI) of brain

- Patients should be on non-increasing dose of steroids for >7 days prior to starting
study drug

- Multifocal disease is eligible

- Age ≥ 18 years

- Karnofsky Performance Status (KPS) ≥70

- Absolute Neutrophil Count ≥1.0 x 10 9/L

- Hemoglobin (Hgb) ≥9 g/dL

- Platelets ≥100 x 10 9/L

- Serum creatinine ≤1.5 x ULRR or measured 24-hr CrCl ≥50mL/min/1.73m2

- Life expectancy ≥ 12 weeks

- Written informed consent obtained prior to screening procedures

- Negative Beta-HCG pregnancy test for women of child-bearing potential

Exclusion Criteria:

- Laboratory Results:

- Serum direct bilirubin >1.5 x upper limit of normal (ULN) of reference range

- Serum creatinine >1.5 x ULRR & CrCl <30 mL/min

- Potassium, <4.0 mmol/L despite supplementation; serum calcium, magnesium out of
normal range despite supplementation

- ALT or AST > 2.5 x ULRR

- Evidence of severe/uncontrolled systemic disease or any concurrent condition which in
Investigator's opinion makes it undesirable for patient to participate in trial or
which would jeopardize compliance with protocol

- Clinically significant cardiovascular event such as myocardial infarction, superior
vena cava syndrome, New York Heart Association classification of heart disease >2
within 3 months before entry; or presence of cardiac disease that, in opinion of
Investigator, increases risk of ventricular arrhythmia

- History of arrhythmia which is symptomatic/requires treatment/asymptomatic sustained
ventricular tachycardia. Atrial fibrillation, controlled on medication is not
excluded.

- Previous history of QTc prolongation as result from other medication that required
discontinuation of that medication

- Congenital long QT syndrome, or 1st degree relative with unexplained sudden death <40
years

- Presence of left bundle branch block

- QTc with Bazett's correction that's unmeasureable, or ≥ 480msec on screening EEG.

- Any concomitant medication that may cause QTc prolongation, induce Torsades de
Pointes/induce CYP3A4 function except for EIAEDs

- Hypertension not controlled by medical therapy

- Currently active diarrhea that may affect ability of patient to absorb study
regimen/tolerate diarrhea

- Women who are currently pregnant/breast feeding

- Previous or current malignancies of other histologies the last year, with exception
of cervical carcinoma in situ & adequately treated basal cell or squamous cell
carcinoma of skin

- Receipt of any investigational agents <30 days prior to commencing study treatment
unless pt has recovered from all anticipated toxicities of investigational agent

- Last dose of prior chemo discontinued < 4 weeks before start of study therapy unless
pt has recovered from all anticipated toxicities of chemo

- Last XRT < 4 weeks before start of study therapy, unless patient has recovered from
all anticipated toxicities of XRT

- Any unresolved toxicity >CTC gr1 from previous anti-cancer therapy

- Previous enrollment/randomization of treatment in present study

- Major surgery < 4 weeks/incompletely healed surgical incision before starting study
therapy

- Patients who have received prior oral VEGFR, EGFR or PDGFR-directed therapies.
Patients who received prior Avastin will be eligible as long as at least 6 weeks has
elapsed since last dose.

- Patients taking warfarin sodium